Source: https://patents.justia.com/patent/8946208
Timestamp: 2019-12-08 08:31:50
Document Index: 152067168

Matched Legal Cases: ['Application No. 200880114062', 'Application No. 2008291873', 'Application No. 97133070', 'Application No. 2010', 'Application No. 2010', 'Application No. 2008291873', 'Application No. 08', 'Application No. 2010']

US Patent for Non-aqueous pharmaceutical composition Patent (Patent # 8,946,208 issued February 3, 2015) - Justia Patents Search
Justia Patents Bicyclo Ring System Having The Seven-membered Hetero Ring As One Of The CyclosUS Patent for Non-aqueous pharmaceutical composition Patent (Patent # 8,946,208)
1. A non-aqueous liquid composition for intranasal delivery of a benzodiazepine drug consisting essentially of:
(ii) a non-aqueous vehicle consisting essentially of about 30 to 85% v/v propylene glycol and 15 to 70% v/v propylene carbonate,
wherein the non-aqueous liquid composition is suitable for delivery in a form of drops or a spray.
2. A composition according to claim 1, wherein the drug is selected from alprazolam, chlordiazepoxide, clonazepam, clorazepate, diazepam, estazolam, flurazepam, halazepam, lorazepam, midazolam, nitrazepam, oxazepam, prazepam, quazepam, temazapem, bromazepam, flunitrazepam, triazolam, bentazepam, brotizolam, clotiazepam, delorazepam, ethyl loflazepate, etizolam, fludiazepam, ketozolam, loprazolam, lormetazepam, nordazepam, mexazolam, nimetazepam, pinazepam and tetrazepam.
4. A method for intranasal delivery of a benzodiazepine drug to a patient in need thereof, the method comprising providing a non-aqueous liquid composition consisting essentially of a benzodiazepine drug and a non-aqueous vehicle for the drug, the vehicle consisting essentially of about 30 to 85% v/v propylene glycol and 15 to 70% v/v propylene carbonate; and intranasally administering the non-aqueous liquid composition to the patient in a form of drops or a spray.
5. A method according to claim 4, wherein the drug is selected from alprazolam, chlordiazepoxide, clonazepam, clorazepate, diazepam, estazolam, flurazepam, halazepam, lorazepam, midazolam, nitrazepam, oxazepam, prazepam, quazepam, temazapem, bromazepam, flunitrazepam, triazolam, bentazepam, brotizolam, clotiazepam, delorazepam, ethyl loflazepate, etizolam, fludiazepam, ketozolam, loprazolam, lormetazepam, nordazepam, mexazolam, nimetazepam, pinazepam and tetrazepam.
6. A method according to claim 5, wherein the drug is diazepam, lorazepam, clonazepam or midazolam.
7. A composition according to claim 1, wherein the non-aqueous vehicle consists essentially of 45 to about 80% v/v propylene glycol and about 20 to 55% v/v propylene carbonate.
8. A composition according to claim 1, consisting essentially of:
(i) about 10 to about 80 mg/mL diazepam; and
(ii) a non-aqueous vehicle consisting essentially of about 50 to about 80% by volume propylene glycol and about 20 to about 50% by volume propylene carbonate.
9. A composition according to claim 3, wherein the drug is diazepam.
10. A method according to claim 6, wherein the drug is diazepam.
11. A composition according to claim 8, wherein the non-aqueous vehicle consists essentially of about 50% to 75% v/v propylene glycol and 25% to about 50% v/v propylene carbonate.
12. A composition according to claim 1, wherein the drug consists of diazepam and the non-aqueous vehicle consists of propylene glycol and propylene carbonate.
13. A composition according to claim 12, wherein the non-aqueous vehicle consists of 45% to about 80% v/v propylene glycol and about 20% to 55% v/v propylene carbonate.
14. A composition according to claim 13, wherein the drug consists of about 10 to about 80 mg/mL diazepam; and the non-aqueous vehicle consists of about 50% to 75% v/v propylene glycol and 25% to about 50% v/v propylene carbonate.
15. A composition according to claim 1 having a viscosity of less than about 100 cP.
16. A composition according to claim 15 having a viscosity of less than 60 cP.
17. A composition according to claim 16 having a viscosity of less than 30 cP.
18. A method according to claim 4, wherein the non-aqueous liquid composition has a viscosity of less than about 100 cP.
19. A method according to claim 18, wherein the non-aqueous liquid composition has a viscosity of less than 60 cP.
20. A method according to claim 19, wherein the non-aqueous liquid composition has a viscosity of less than 30 cP.
21. A method for treating anxiety or epilepsy or for inducing sedation or anticonvulsant actions, the method comprising providing a non-aqueous liquid composition consisting essentially of a benzodiazepine drug selected from diazepam, lorazepam, clonazepam and midazolam in an amount effective for treating anxiety or epilepsy or for inducing sedation or anticonvulsant actions, and a non-aqueous vehicle consisting essentially of about 30 to 85% v/v propylene glycol and 15 to 70% v/v propylene carbonate; and intranasally administering the non-aqueous liquid composition to the patient in a form of drops or a spray.
22. A method according to claim 21 for treating epilepsy.
23. A method according to claim 21 for inducing anticonvulsant actions.
24. A method according to claim 21, wherein the benzodiazepine drug is diazepam or midazolam.
25. A method according to claim 24, wherein the benzodiazepine drug is diazepam.
26. A method according to claim 25 for treating epilepsy.
27. A method according to claim 25 for inducing anticonvulsant actions.
5589475 December 31, 1996 Snorrason et al.
6627211 September 30, 2003 Choi et al.
6767533 July 27, 2004 Casellas et al.
20030180364 September 25, 2003 Chen et al.
20040176359 September 9, 2004 Wermeling
20050287181 December 29, 2005 Murthy
20070071687 March 29, 2007 Wermeling
20080070904 March 20, 2008 Jamieson et al.
20080279784 November 13, 2008 Cartt et al.
1 374 855 January 2004 EP
08-333244 December 1996 JP
01/06987 February 2001 WO
2005/067893 July 2005 WO
2005117830 December 2005 WO
2006/041942 April 2006 WO
2006/122217 November 2006 WO
2007056424 May 2007 WO
2008027357 March 2008 WO
2009/046444 April 2009 WO
Martindale: “The Complete Drug Reference”, 1999, Pharmaceutical Press, 32nd. Ed., pp. 635-639.
A. Gringauz, “Introduction to Medicinal Chemistry: How Drugs Act and Why”, 1997, pp. 578-586.
Goodman & Gilman's, “The Pharmacological Basis of Therapeutics”, 9th Ed., McGraw Hill, 1996, p. 383.
S. Bjorkman et al., “Pharmacokinetics of midazolam given as an intranasal spray to adult surgical patients”, British Journal of Anaesthesia, 1997; 79: pp. 575-580.
Niall C. T. Wilton, et al., “Preanesthetic Sedation of Preschool Children Using Intranasal Midazolam”, Anesthesiology, vol. 69, No. 6, Dec. 1988, pp. 972-975.
Chung Y.Lui et al., “Intranasal Absorption of Flurazepam, Midazolam, and Triazolam in Dogs”, Journal of Pharmaceutical Sciences, vol. 80, No. 12, Dec. 1991, pp. 1125-1129.
Erik Bechgaard, et al., “Pharmacokinetic and Pharmacodynamic Response after Intranasal Administration of Diazepam to Rabbits”, J. Pharm. Pharmacol. 1997, 49; pp. 747-750.
S.W.J. Lau, et al., “Absorption of diazepam and lorazepam following intranasal administration”, International Journal of Pharmaceutics, Elsevier Science Publishers B.V., 1989, 54, pp. 171-174.
S.H. Yalkowsky, et al., “Solubilization by Cosolvents I: Organic Solutes in Propylene Glycol-Water Mixtures”, Journal of Pharmaceutical Sciences, vol. 74, No. 4, Apr. 1985, pp. 416-421.
Handbook of Pharmaceutical Excipients, Pharmaceutical Press, London and American Pharmacists Association, Washington, 2003, 4th Ed., 23 pages.
Bechgaard, Erik, et al. “Solubilization of Various Benzodiazepines for Intranasal Administration, a Pilot Study”, Pharmaceutical Development and Technology, 2(3), 293-296 (1977).
Nielsen, Hanne W. et al., “Solubilization and Stability of Bumetanide in Vehicles for Intranasal Administration, a Pilot Study”; Pharmaceutical Development and Technology, 6(2), 145-149 (2001).
Hjortkjaer, Rolf, et al., “Single-and Repeated-dose Local Toxicity in the Nasal Cavity of Rabbits after Intranasal Administration of Different Glycols for Formulations Containing Benzodiazepines”; J. Pharm. Pharmacol. 1999, 51:377-383.
Int'l Search Report and Written Opinion dated Feb. 11, 2010 in Int'l Application No. PCT/GB2008/002940, 21 pages.
Office Action dated Nov. 26, 2010 in NZ Patent Appln. No. 583265, 2 pages.
Handbook of Pharmaceutical Excipients, 6th Ed., Pharmaceutical Press, London—Chicago, pp. 517-591, 2009.
Notification of Grant issued May 3, 2012 in CN Application No. 200880114062.8.
Office Action issued Jun. 27, 2013 in AU Application No. 2008291873.
Office Action issued Aug. 1, 2013 in MX Application No. MX/a/2010/001911.
Office Action issued Apr. 30, 2013 in TW Application No. 97133070.
Office Action issued Jun. 11, 2013 in JP Application No. 2010-522446.
Office Action issued Nov. 12, 2013 in JP Application No. 2010-522446.
Notice of Acceptance issued Apr. 16, 2014 in Australian Application No. 2008291873.
Certificate of Patent for Japanese Patent No. 5539875 registered May 9, 2014.
Office Action issued Apr. 24, 2014 in EP Application No. 08 788 485.4.
Anonymous, “Handbook of Pharmaceutical Excipients,” 5th edition (2006).
Office Action issued Feb. 7, 2014 in MX Application No. MX/a/2010/001911.
Office Action issued Feb. 13, 2014 in TW Applicaiton No. 097133070.
Notice of Allowance issued Apr. 7, 2014 in JP Application No. 2010-522446.
Patent Publication Number: 20090233912
Current U.S. Class: Bicyclo Ring System Having The Seven-membered Hetero Ring As One Of The Cyclos (514/221); Tricyclo Ring System Having The Seven-membered Hetero Ring As One Of The Cyclos (514/220); The Bicyclo Ring System Is 1,4-benzodiazepine (including Hydrogenated) (540/504)
International Classification: A01N 43/62 (20060101); A61K 31/55 (20060101); C07D 243/12 (20060101); A61K 9/00 (20060101); A61K 9/08 (20060101); A61K 31/5517 (20060101); A61K 47/10 (20060101); A61K 47/14 (20060101); A61K 47/22 (20060101);